The new drug application is supported by 48-week data from the Phase III MK-8591A-051 and MK-8591A-052 trials, which showed ...

A panel of key opinion leaders consider how payers and manufacturers are increasingly embracing innovative contracting models ...

The majority of respondents not already enrolled in the program have concerns that the program won’t survive until the point ...

Bravecto Quantum is the first FDA-approved drug that treats and prevents flea and tick infestations on dogs for a duration of ...

The specific parameters defined in your label, including patient population, line of therapy, and outcomes measured, will now ...

rs6190 helps men build muscle mass and reduce diabetes risk, but increases cholesterol levels and elevates the risk of ...

The new doll will include an insulin pump, a glucose monitor, and a dress featuring international symbols for diabetes ...

Renee Gala named next CEO of Jazz Pharmaceuticals: Gala will take over as president and CEO on August 11, 2025, following ...

Approval was based on results from the Phase IIIb TRAILBLAZER-ALZ 6 trial, which showed that Kisunla achieved comparable ...

Marcel Botha discusses ways the agency can ensure it gets the most accurate results possible from AI.

TPN-101, a potent nucleoside reverse transcriptase inhibitor that specifically inhibits the LINE-1 reverse transcriptase.

Life sciences marketing has long revolved around physicians. Traditionally seen as the gatekeepers of prescribing power, ...